外部驱动主要终点变更下的成组序贯设计
本文探讨自适应试验中因外部因素变更主要终点时,如何调整成组序贯方法以控制新主要终点的总体I类错误率。方法允许不依赖初始主要终点的真实疗效,通过模拟研究证明当两终点相关性由试验数据估计时I类错误率仍受控,并以瑞德西韦治疗COVID-19的模拟数据示例说明。
要点
- 外部驱动变更主要终点时,若仍按原终点监测进行校正可能保守,不校正则可能因终点相关而膨胀I类错误率。
- 提出的成组序贯方法可控制新主要终点分析的I类错误率,不受初始主要终点真实疗效影响。
- 模拟研究显示,当两终点相关性由试验数据估计时,I类错误率仍得到控制。
核心结论
- 本文展示如何修改成组序贯方法以控制新主要终点分析的I类错误率,且不依赖初始主要终点的真实疗效。
研究设计与样本
- 方法学研究,通过模拟数据示例(基于瑞德西韦治疗COVID-19的临床试验)说明方法,并进行模拟研究评估I类错误率控制情况。
主要发现
- 若按初始主要终点监测进行校正可能保守,而不做任何校正则在新旧终点相关时可能膨胀I类错误率。
- 模拟研究证明,当新主要终点与初始主要终点的相关性由试验中两终点数据估计时,I类错误率得到控制。
关键数值与推荐
- 构建新主要终点检验的临界值需要新主要终点与初始主要终点之间的相关系数。
- 模拟研究显示,当该相关系数由试验中两终点数据估计时,I类错误率受控。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials conducted during the COVID-19 pandemic demonstrated the value of adaptive design methods in emerging disease settings, when there can be considerable uncertainty around disease natural history, anticipated endpoint effect sizes and population size. In such settings, there may also be uncertainty regarding the most appropriate primary endpoint. This might lead to an externally-driven decision to change the primary endpoint during the course of an adaptive trial. If information on the new primary endpoint is already being collected, initially as a secondary endpoint, the trial could continue with a new primary endpoint. In this case it is unclear how statistical inference on the final primary endpoint should be adjusted for interim analyses monitoring the initial primary endpoint so as to control the overall type I error rate as adjusting for monitoring as if this was based on the new endpoint could be conservative whereas failing to make any adjustment could lead to type I error rate inflation if the new and original endpoint are correlated. This paper shows how group-sequential methods can be modified to control the type I error rate for the analysis of the new primary endpoint irrespective of the true treatment effect on the initial primary endpoint. The method is illustrated using a simulated data example based on a clinical trial of remdesivir in COVID-19. Construction of critical values for the test of the new primary endpoint require a value for the correlation between this and the initial primary endpoint. We present simulation studies to demonstrate that the type I error rate is controlled when this value is estimated from the data on the two endpoints obtained from the trial.
引用
- Yarahmadi A, Dodd LE, Horby P, et al. Group-Sequential Designs With an Externally-Driven Change of Primary Endpoint. Stat Med. 2025. PMID: 41370091. doi:10.1002/sim.70337
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。